In the realm of drug development, focusing on key enzymes and transporters involved in ketone metabolism, such as BDH1 and SCOT, novel therapeutics could provide more targeted and effective treatment options for heart failure patients by targeting ketone metabolism pathways. The gene discussed is BDH1; the disease is heart failure.